(146) observed significant blood-to-brain influx for non-acylated GLP-1 mimetics like exendin-4 and lixisenatide, whereas acylated GLP-1 analogues such as liraglutide and semaglutide showed minimal blood-brain barrier penetration in mice
Jared Holz thought about taking one of the new GLP-1 drugs for weight loss for months before he actually filled the prescription
Receive News
PA, AMPK inhibitor compound C and GLP-1R antagonist exendin (939) were purchased from Sigma (St
[DOI] [PMC free article] [PubMed] [Google Scholar] [16].Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, Hardt-Lindberg S, Hovingh GK, Kahn SE, Kushner RF, Lingvay I, Oral TK, Michelsen MM, Plutzky J, Torne CW, Ryan DH, Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes, N Engl J Med (2023)
Summary GLP-1RA-mediated weight loss is achieved through multiple pathways including effects on the central nervous system such as reduced appetite, energy intake, and hunger, increased feelings of satiety, and altered food preferences
